BRIEF-Adc Therapeutics Announces Completion Of Enrollment Of Phase 3 Confirmatory Clinical Trial Of Zynlonta In Combination With Rituximab In 2L+ Diffuse Large B-Cell Lymphoma
ReutersDec 30, 2024 9:51 PM
Dec 30 (Reuters) - ADC Therapeutics SA ADCT.N:
ADC THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT OF PHASE 3 CONFIRMATORY CLINICAL TRIAL OF ZYNLONTA® IN COMBINATION WITH RITUXIMAB IN 2L+ DIFFUSE LARGE B-CELL LYMPHOMA
Source text: ID:nPn4FzrXCa
Further company coverage: ADCT.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
The Ultimate AI Investment Guide:Opportunities, Risks, and Strategies for the Next Generation of Technology Markets
TradingKey - OpenAI’s recent multi-billion-dollar partnerships—with Nvidia, AMD, and Broadcom—have flooded headlines and lifted markets, but they’ve also sparked a new round of debate: Is Sam Altman steering us toward a runaway tech bubbleTradingKey
11 hours ago
RTX: Driving Breakthroughs in Defense Technology and Commercial Aviation
RTX Corporation (NYSE: RTX) is a dominant force in aerospace and defense, perfectly positioned to ride the wave of growing global defense budgets and a booming commercial aviation market.TradingKey
Mon, Aug 11
Amazon Q2 FY2025 Earnings Review: Robust Cloud and AI Growth Coupled with Retail Tariff Challenges
TradingKey - Amazon.com, Inc. (NASDAQ: AMZN) released its Q2 FY2025 earnings on July 31, 2025, after market close, delivering results that surpassed expectations, driven by robust growth in AWS, advertising, and retail segments.TradingKey
Fri, Aug 1
From Treehouses to Castles: How Airbnb Is Disrupting the Traditional Travel Market
TradingKey - Airbnb, as the global leader in the short-term rental market, leverages diverse listings, Remote Work Hubs, and Airbnb Experiences to effectively capture post-pandemic demand for flexible accommodations and personalized travel, achieving a 44% market share in 2024, far ahead of...TradingKey
Mon, Jul 28
